PHIO News and Press, Phio Pharmaceuticals Corp. From 09/22/22

Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference PR Newswire MARLBOROUGH, Mass. , Sept. 22, 2022 /PRN...

Phio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) PR Newswire MARLBOROUGH, Mass. , Sept. 12, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage bio...

Phio Pharmaceuticals press release ( NASDAQ: PHIO ): Q2 GAAP EPS of -$0.19 beats by $0.12 . At June 30, 2022, the Company had cash of $18.0 million as compared with $24.1 million at December 31, 2021. The Company expects its current cash will be sufficient to fund ...

Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update PR Newswire Initiated dosing of subjects and enrollment ongoing in the first-in-human clinical study of PH-762 for the treatment of advanced melanoma; expect to announce top...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com It’s time for another dive into the biggest pre-market stock movers as we go over the news for Tuesday morning! We’ve got clinical trials, collaboration agreements...

Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting PR Newswire MARLBOROUGH, Mass. , June 6, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical s...

Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022 PR Newswire MARLBOROUGH, Mass. , May 16, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company...

Phio Pharmaceuticals press release (NASDAQ:PHIO): Q1 GAAP EPS of -$0.19 beats by $0.11. At March 31, 2022, the Company had cash of $20.5 million as compared with $24.1 million at December 31, 2021. The Company expects its current cash will be sufficient to fund currently planned operations to...

Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update PR Newswire First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment Expect to finalize IND-enabling studies for PH-894 in t...

Phio Pharmaceuticals Announces Senior Leadership Personnel Change PR Newswire MARLBOROUGH, Mass. , May 5, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics...